Clinical Study

Prospective Evaluation of Whole Genome MicroRNA Expression Profiling in Childhood Acute Lymphoblastic Leukemia

Table 2

Significant miRNA profile compared to control cases in the microarray study and validation results in real time RT-PCR. According to mean values, only those miRNAs whose “fold change” value demonstrated ± 2-fold or more expression difference were included in the study. miRNAs whose “False Discovery Rate” (FDR) corrected value <0.05 were considered significant. FDR is calculated by using CLC Main Workbench 5 (CLC Bio, Denmark). A total of 13 miRNAs showed upregulation (shown in bold) and 2 miRNAs showed downregulation.

miRNA MicroarrayHigh/Low Expression ( )*RT-PCRHigh/Low Expression ( )*
ControlALLRatio valueFDR ControlALL

hsa-miR-548i1.8422.1212.503.90 30.0323/00.0001120.0079426.150.59021/0
hsa-miR-70846.55488.7710.006.55 40.0121/70.00294919.0116712.650.29128/3
hsa-miR-181b72.46467.476.257.09 6 36/30.046848.4243110.020.25133/2
hsa-miR-449a6.6623.843.572.69 30.0314/00.0036530.0131431.850.1637/0
hsa-miR-146a326.651135.733.458.31 51.79 335/20.06818924.372518.480.00835/1
hsa-miR-155170.68515.253.037.93 51.79 332/20.06302731.669878.970.00934/0
hsa-miR-181a * 104.93298.172.866.54 30.0425/40.0123410.7666045.960.12335/2
hsa-miR-312112.0433.642.786.95 30.0421/00.0238030.001278−4.220.2090/0
hsa-miR-181a661.351810.682.703.66 30.0329/70.77055680.630696.710.00234/2
hsa-miR-128720.721713.492.382.67 62.88 430/00.24555611.39625.540.00933/4
hsa-miR-132334.2181.962.381.05 30.0125/20.0006860.000024−4.840.1990/0
hsa-miR-195962.762251.432.339.67 40.0128/40.0124331.2505046.65<0.00132/3
hsa-miR-58733.8369.932.085.67 30.0417/40.0005230.000146−1.840.3261/0
hsa-miR-64091.5345.07−2.037.18 30.043/300.0502270.000498−6.660.1910/0
hsa-miR-145498.27197.73−2.528.09 51.79 32/351.20144414.559613.600.44026/10

FDR: false discovery rate, ALL: acute lymphoblastic leukemia.
*“High/Low Expression ( )” means the number of cases in which particular miRNA expression is over the normal range. Normal range was accepted for the 95% CI of control cases.